RP1 : Clinical data presented at the 34 th Annual Meeting of the Society for Immunotherapy of Cancer ( SITC 2019) confirmed expected safety profile and mechanism of action: Efficacy data supports ongoing and expanded programs in cutaneous squamous cell carcinoma (CSCC) and melanoma RP1 : Announced